DK2760471T3 - Terapeutiske peptider - Google Patents

Terapeutiske peptider Download PDF

Info

Publication number
DK2760471T3
DK2760471T3 DK12835118.6T DK12835118T DK2760471T3 DK 2760471 T3 DK2760471 T3 DK 2760471T3 DK 12835118 T DK12835118 T DK 12835118T DK 2760471 T3 DK2760471 T3 DK 2760471T3
Authority
DK
Denmark
Prior art keywords
antibody
seq
ser
artificial sequence
gly
Prior art date
Application number
DK12835118.6T
Other languages
English (en)
Inventor
Kai W Wucherpfennig
Kenneth May Jr
Glenn Dranoff
F Stephen Hodi
Christopher Harvey
Bettina Franz
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of DK2760471T3 publication Critical patent/DK2760471T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (14)

  1. TERAPEUTISKE PEPTIDER
    1. Sammensætning omfattende et antistof eller antistoffragment, der immunspecifikt binder til MHC klasse I polypeptid-relateret sekvens A (MICA), hvor antistoffet eller antistoffragmentet omfatter en variabel tungkæderegion (VH) og en variabel letkæderegion (VL) og, (a) komplementaritetsbestemmende region (CDR) 3 ifølge SEQ ID NO: 212 af VH af antistof ID 9; eller (b) komplementaritetsbestemmende region (CDR) 3 ifølge SEQ ID NO: 158 af VH af antistof ID 6.
  2. 2. Sammensætning ifølge krav 1, hvor antistoffet eller antistoffragmentet omfatter, (a) komplementaritetsbestemmende region (CDR) 3 ifølge SEQ ID NO: 212 af VH af antistof ID 9, og CDR3 ifølge SEQ ID NO: 219 af VL af antistoflD 9; eller (b) komplementaritetsbestemmende region (CDR) 3 ifølge SEQ ID NO: 158 af VH af antistof ID 6, og CDR3 ifølge SEQ ID NO: 164 af VL af antistof ID 6.
  3. 3. Sammensætning ifølge krav 1 eller krav 2, hvor antistoffet eller antistoffragmentet ifølge (a) endvidere omfatter komplementaritetsbestemmende region CDR2 ifølge SEQ ID NO: 210 af VH af antistof ID 9, og CDR2 ifølge SEQ ID NO: 217 af VL af antistof ID 9; eller hvor peptidet ifølge (b) endvidere omfatter komplementaritetsbestemmende region CDR2 ifølge SEQ ID NO: 156 af Vh af antistof ID 6, og CDR2 ifølge SEQ ID NO: 162 af VL af antistoflD 6.
  4. 4. Sammensætning ifølge et hvilket som helst af kravene 1-3, hvor antistoffet eller antistofifragmentet ifølge (a) omfatter komplementaritetsbestemmende region CDR1 ifølge SEQ ID NO: 208 af VH af antistof ID 9, og CDR1 ifølge SEQ ID NO: 215 af VL af antistof ID 9; eller hvor peptidet ifølge (b) omfatter komplementaritetsbestemmende region CDR1 ifølge SEQ ID NO: 153 afVH af antistoflD 6, og CDR1 ifølge SEQ ID NO: 160 af VL af antistoflD 6.
  5. 5. Sammensætning ifølge et hvilket som helst af kravene 1-4, hvor antistoffet eller antistoffragmentet omfatter: (a) en VH-kæde med mindst 95 %, 96 %, 97 %, 98 eller 99 % identitet med SEQ ID NO: 204; eller (b) en VH-kæde med mindst 95 %, 96 %, 97 %, 98 eller 99 % identitet med SEQ ID NO: 149.
  6. 6. Sammensætning ifølge et hvilket som helst af kravene 1-5, hvor antistoffet eller antistoffragmentet omfatter (a) en VL-kæde med mindst 95 %, 96 %, 97 %, 98 eller 99 % identitet med aminosyresekvensen ifølge SEQ ID NO: 206, hvor VL ikke omfatter mere end én aminosyresubstitution inde i CDR’eme i forhold til VL-CDR1-aminosyresekvensen ifølge SEQ ID NO: 215, VL, CDR2-aminosyresekvensen ifølge SEQ ID NO: 217 og VL-CDR3-aminosyresekvensen ifølge SEQ ID NO: 219; eller (b) en VL-kæde med mindst 95 %, 96 %, 97 %, 98 eller 99 % identitet med aminosyresekvensen ifølge SEQ ID NO: 151, hvor VL ikke omfatter mere end én aminosyresubstitution inde i CDR’eme i forhold til VL-CDRl-aminosyresekvensen ifølge SEQ ID NO: 160, VL-CDR2-aminosyresekvensen ifølge SEQ ID NO: 162 og VL-CDR3-aminosyresekvensen ifølge SEQ ID NO: 164.
  7. 7. Sammensætning ifølge et hvilket som helst af kravene 1-6, hvor antistoffet eller antistoffragmentet omfatter (a) en VH-CDR1, der omfatter aminosyresekvensen ifølge SEQ ID NO: 208, en VH-CDR2, der omfatter aminosyresekvensen ifølge SEQ ID NO: 210, en VH-CDR3, der omfatter aminosyresekvensen ifølge SEQ ID NO: 212, en VL-CDR1, der omfatter aminosyresekvensen ifølge SEQ ID NO: 215, en VL-CDR2, der omfatter aminosyresekvensen ifølge SEQ ID NO: 217 og en VL-CDR3, der omfatter aminosyresekvensen ifølge SEQ ID NO: 219; eller (b) en Vh-CDR1, der omfatter aminosyresekvensen ifølge SEQ ID NO: 153, en VH-CDR2, der omfatter aminosyresekvensen ifølge SEQ ID NO: 156, en VH-CDR3, der omfatter aminosyresekvensen ifølge SEQ ID NO: 158, en Vl-CDR1, der omfatter aminosyresekvensen ifølge SEQ ID NO: 160, en VL-CDR2, der omfatter aminosyresekvensen ifølge SEQ ID NO: 162 og en VL-CDR3, der omfatter aminosyresekvensen ifølge SEQ ID NO: 164.
  8. 8. Sammensætning ifølge krav 7, hvor antistoffet eller antistoffragmentet omfatter (a) en VH med mindst 95 %, 96 %, 97 %, 98 % eller 99 % identitet med aminosyresekvensen ifølge SEQ ID NO: 204 og en VL-kæde med mindst 95 %, 96 %, 97 %, 98 % eller 99 % identitet med aminosyresekvensen ifølge SEQ ID NO: 206; eller VH-kæde med mindst 95 %, 96 %, 97 %, 98 % eller 99 % identitet med aminosyresekvensen ifølge SEQ ID NO: 149 og en VT,-kæde med mindst 95 %, 96 %, 97 %, 98 % eller 99 % identitet med aminosyresekvensen ifølge SEQ ID NO: 151.
  9. 9. Sammensætning ifølge krav 8, hvor antistoffet eller antistoffragmentet omfatter en VH-kæde, der omfatter SEQ ID NO: 204 og en VL-kæde, der omfatter SEQ ID NO: 206; eller en VH-kæde, der omfatter SEQ ID NO: 149 og en VL-kæde, der omfatter SEQ ID NO: 151.
  10. 10. Sammensætning ifølge et hvilket som helst af kravene 1-9, hvilken sammensætning endvidere omfatter et anticancermiddel.
  11. 11. Sammensætning ifølge et hvilket som helst af kravene 1-10 formuleret som en farmaceutisk sammensætning.
  12. 12. Sammensætning ifølge et hvilket som helst af kravene 1-11, hvilken sammensætning endvidere omfatter en histondeacetylasehæmmer (HDAC) udvalgt fra gruppen bestående af hydroxamsyre, vorinostat, suberoylanilid-hydiOxamsyre (SAHA, trichostatin A (TSA), LAQ824, panobinostat (LBH589), belinostat (PXD101), ITF2357 italfarmaco SpA, cyklisk tetrapeptid, depsipeptid (romidepsin, FK228), benzamid; entinostat (SNDX-275/MS-275), MGCD0103, kortkædede alifatiske syrer, valproinsyre, phenylbutyrat, AN-9, pivanex, CHR-3996 og CHR-2845.
  13. 13. Sammensætning ifølge et hvilket som helst af kravene 1-12, hvilken sammensætning endvidere omfatter en proteasom-hæmmer udvalgt fra gruppen bestående af bortezomib, NPI-0052, carfilzomib (PR-171), CEP 18770, ogMLN9708.
  14. 14. Sammensætning ifølge et hvilket som helst af kravene 1-13, hvilken sammensætning endvidere omfatter et antistof udvalgt fra gruppen bestående af et anti-CTLA-4-antistof, et anti-PD-1 antistof, et anti-PDL-1 antistof og en kombination af ét eller flere deraf.
DK12835118.6T 2011-09-30 2012-09-28 Terapeutiske peptider DK2760471T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541921P 2011-09-30 2011-09-30
PCT/US2012/057839 WO2013049517A2 (en) 2011-09-30 2012-09-28 Therapeutic peptides

Publications (1)

Publication Number Publication Date
DK2760471T3 true DK2760471T3 (da) 2017-05-08

Family

ID=47996757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12835118.6T DK2760471T3 (da) 2011-09-30 2012-09-28 Terapeutiske peptider

Country Status (29)

Country Link
US (2) US9402905B2 (da)
EP (3) EP2760471B9 (da)
JP (2) JP2014532053A (da)
KR (2) KR102017070B1 (da)
CN (2) CN107098967A (da)
AU (1) AU2012315792B2 (da)
BR (1) BR112014007487A2 (da)
CA (1) CA2850542A1 (da)
CL (1) CL2014000786A1 (da)
CO (1) CO7020866A2 (da)
CY (1) CY1119567T1 (da)
DK (1) DK2760471T3 (da)
EA (1) EA201490644A1 (da)
ES (3) ES2619707T3 (da)
HK (2) HK1199835A1 (da)
HR (1) HRP20170494T1 (da)
HU (1) HUE034044T2 (da)
IL (1) IL231604B (da)
LT (1) LT2760471T (da)
MX (1) MX355877B (da)
NZ (2) NZ623086A (da)
PE (1) PE20142361A1 (da)
PL (1) PL2760471T3 (da)
PT (1) PT2760471T (da)
RS (1) RS55822B1 (da)
SG (1) SG11201401104WA (da)
SI (1) SI2760471T1 (da)
TN (1) TN2014000134A1 (da)
WO (1) WO2013049517A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083857A4 (en) * 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
BR112014007487A2 (pt) 2011-09-30 2017-04-04 Dana Farber Cancer Inst Inc peptídeos terapêuticos
AU2013218017B2 (en) 2012-02-07 2017-12-07 Innate Pharma MICA binding agents
EP2970490A4 (en) 2013-03-15 2017-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
AU2014228502A1 (en) * 2013-03-15 2015-08-20 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
EP3708189B1 (en) 2013-07-05 2023-11-29 University of Washington through its Center for Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
CA2932767A1 (en) * 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CN106456728A (zh) 2014-03-14 2017-02-22 达纳－法伯癌症研究所公司 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
EP3145953A1 (en) * 2014-05-21 2017-03-29 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
EP3383426A1 (en) 2015-12-04 2018-10-10 Dana Farber Cancer Institute, Inc. Vaccination with mica/b alpha 3 domain for the treatment of cancer
US10448746B2 (en) * 2016-03-15 2019-10-22 Nadia Galloway Bed sheet with an integrated body positioner
AU2017235274A1 (en) * 2016-03-15 2018-08-16 Innate Pharma Anti-mica antibodies
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018022831A1 (en) * 2016-07-28 2018-02-01 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
US11066471B2 (en) 2016-10-19 2021-07-20 Novelogics Biotechnology Inc. Antibodies to MICA and MICB proteins
JP2019535250A (ja) * 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
US20210101980A1 (en) 2017-03-31 2021-04-08 Bristol-Myers Squibb Company Methods of treating tumor
WO2019075468A1 (en) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company TUMOR TREATMENT METHODS
EP3743109A4 (en) * 2018-01-25 2021-11-10 Cullinan Mica Corp. ANTI-MICA / B ANTIBODIES AND THEIR METHODS OF USE
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020035345A1 (en) * 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CN113637077B (zh) * 2021-10-14 2021-12-24 尚健单抗（北京）生物技术有限公司 一种抗mica的抗体及其应用

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
WO1988007054A1 (en) 1987-03-18 1988-09-22 Research Corporation Limited Complement-binding peptide
GB8709290D0 (en) 1987-04-16 1987-05-20 Secretary Trade Ind Brit Precision motion slideways
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998019167A2 (en) 1996-10-29 1998-05-07 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002068615A2 (en) 2001-02-28 2002-09-06 Fred Hutchinson Cancer Research Center, Inc. Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
US6566208B2 (en) 2001-07-25 2003-05-20 Chartered Semiconductor Manufacturing Ltd. Method to form elevated source/drain using poly spacer
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7771718B2 (en) * 2002-04-22 2010-08-10 Fred Hutchinson Cancer Research Center Soluble MIC polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
WO2003089906A2 (en) 2002-04-22 2003-10-30 University Of Florida Functionalized nanoparticles and methods of use
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
KR20160003332A (ko) * 2003-06-27 2016-01-08 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005070963A1 (en) 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Fc region variants
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
DE602005015302D1 (en) * 2004-04-05 2009-08-20 Univ California Nkg2d modulation
WO2006020114A2 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Variant fc regions
JP2008520188A (ja) * 2004-10-19 2008-06-19 アムジエン・インコーポレーテツド アンジオポエチン−２特異的結合物質
AU2005306997B2 (en) 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof
US7973140B2 (en) * 2004-12-21 2011-07-05 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
US20080148432A1 (en) * 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
AU2006254902B8 (en) 2005-06-08 2012-08-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
WO2007039404A1 (en) * 2005-09-21 2007-04-12 Nycomed Gmbh Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles
EP1949107A1 (en) 2005-11-03 2008-07-30 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by nkg2d-positive cd4-positive cells
US8248965B2 (en) 2005-11-03 2012-08-21 Motorola Solutions, Inc. Method and apparatus regarding use of a service convergence fabric
JP5179373B2 (ja) * 2005-12-15 2013-04-10 アストラゼネカ アクチボラグ 癌を治療するためのアンジオポエチン−２アンタゴニストとＶＥＧＦ−Ａ、ＫＤＲ、及び／又はＦｌｔ１アンタゴニストの組合せ
DE102006009847A1 (de) 2006-03-01 2007-09-06 Sweredjuk, Robert, Dr. Verfahren von Absorbieren von Schadstoffen und Gerüchen
US8642042B2 (en) 2006-08-07 2014-02-04 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
US20110060120A1 (en) 2006-09-08 2011-03-10 Obeid Michel Sarkis Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57
EP2083857A4 (en) 2006-09-22 2010-03-24 Dana Farber Cancer Res Inc METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
WO2008043018A1 (en) * 2006-10-04 2008-04-10 Dana-Farber Cancer Institute, Inc. Tumor immunity
EP1944611A1 (en) * 2007-01-11 2008-07-16 Université de la Méditerranée Biomarker for the medicine and the biology of the reproduction
EP2150565A2 (en) 2007-04-23 2010-02-10 Fred Hutchinson Cancer Research Center NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5
KR20100021601A (ko) * 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2011063336A2 (en) 2009-11-20 2011-05-26 President And Fellows Of Harvard College Secondary site of antigen stimulation for therapeutic vaccination
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2010011242A2 (en) * 2008-03-24 2010-01-28 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnoisis of systemic anthrax infection
US8182809B1 (en) 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8207497B2 (en) 2009-05-08 2012-06-26 Ionsense, Inc. Sampling of confined spaces
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR101688522B1 (ko) 2009-12-15 2016-12-21 삼성전자주식회사 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
HUE029785T2 (en) * 2010-02-08 2017-04-28 Regeneron Pharma Common mouse light chain
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
CN102911270A (zh) * 2011-08-05 2013-02-06 浙江大学 一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法
BR112014007487A2 (pt) 2011-09-30 2017-04-04 Dana Farber Cancer Inst Inc peptídeos terapêuticos
AU2013218017B2 (en) * 2012-02-07 2017-12-07 Innate Pharma MICA binding agents
AU2014228502A1 (en) 2013-03-15 2015-08-20 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CN105051491B (zh) 2013-03-28 2017-07-25 本田技研工业株式会社 告知系统、电子设备、告知方法及程序
US9572898B2 (en) 2013-09-09 2017-02-21 Seton Hall University Functionalized fluorine containing phthalocyanine molecules
CA2932767A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
CN106456728A (zh) 2014-03-14 2017-02-22 达纳－法伯癌症研究所公司 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
EP3145953A1 (en) 2014-05-21 2017-03-29 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies

Also Published As

Publication number Publication date
KR102225422B1 (ko) 2021-03-08
CN103958543B (zh) 2016-12-14
JP2018048139A (ja) 2018-03-29
EP3210625A2 (en) 2017-08-30
AU2012315792B2 (en) 2017-09-07
CL2014000786A1 (es) 2014-11-14
PL2760471T3 (pl) 2017-07-31
NZ721184A (en) 2018-08-31
AU2012315792A1 (en) 2014-04-17
EA201490644A1 (ru) 2014-09-30
TN2014000134A1 (en) 2015-07-01
KR20140076600A (ko) 2014-06-20
EP3210625B1 (en) 2019-08-28
CO7020866A2 (es) 2014-08-11
CN103958543A (zh) 2014-07-30
US20170008962A1 (en) 2017-01-12
MX355877B (es) 2018-05-03
IL231604B (en) 2018-08-30
PT2760471T (pt) 2017-03-22
LT2760471T (lt) 2017-04-25
US9402905B2 (en) 2016-08-02
NZ623086A (en) 2016-08-26
ES2757473T3 (es) 2020-04-29
IL231604A0 (en) 2014-05-28
HK1199835A1 (en) 2015-07-24
ES2619707T3 (es) 2017-06-26
MX2014003601A (es) 2014-05-28
EP2760471A2 (en) 2014-08-06
SG11201401104WA (en) 2014-09-26
ES2925654T3 (es) 2022-10-19
EP2760471A4 (en) 2015-06-03
CN107098967A (zh) 2017-08-29
SI2760471T1 (sl) 2017-04-26
BR112014007487A2 (pt) 2017-04-04
WO2013049517A3 (en) 2014-05-08
JP2014532053A (ja) 2014-12-04
US10793633B2 (en) 2020-10-06
EP3628329B1 (en) 2022-08-10
WO2013049517A2 (en) 2013-04-04
RS55822B1 (sr) 2017-08-31
PE20142361A1 (es) 2015-01-16
HK1243427A1 (zh) 2018-07-13
CY1119567T1 (el) 2018-03-07
EP2760471B1 (en) 2017-02-01
EP3628329A1 (en) 2020-04-01
CA2850542A1 (en) 2013-04-04
US20140004112A1 (en) 2014-01-02
KR102017070B1 (ko) 2019-09-02
HRP20170494T1 (hr) 2017-06-02
EP2760471B9 (en) 2017-07-19
EP3210625A3 (en) 2017-10-25
HUE034044T2 (en) 2018-01-29
KR20190112756A (ko) 2019-10-07

Similar Documents

Publication Publication Date Title
DK2760471T3 (da) Terapeutiske peptider
US10106611B2 (en) Antibodies that bind to MHC class I polypeptide-related sequence A
JP6397886B2 (ja) 治療用ペプチド
BR112021010402A2 (pt) Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos